| scholarly article | Q13442814 |
| P2093 | author name string | Michael P Lux | |
| Peter A Fasching | |||
| Volkmar Müller | |||
| Johannes Ettl | |||
| Achim Wöckel | |||
| Jens Huober | |||
| Andreas Schneeweiss | |||
| Hans Tesch | |||
| Wolfgang Janni | |||
| Diana Lüftner | |||
| Andreas D Hartkopf | |||
| Manfred Welslau | |||
| Tanja N Fehm | |||
| Florian Schütz | |||
| Marc Thill | |||
| Erik Belleville | |||
| Friedrich Overkamp | |||
| Hans-Christian Kolberg | |||
| Patrik Pöschke | |||
| P2860 | cites work | Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial | Q40914660 |
| 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: | Q41192447 | ||
| Association analysis identifies 65 new breast cancer risk loci. | Q45979098 | ||
| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | Q46103372 | ||
| Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer | Q46782579 | ||
| Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. | Q50754518 | ||
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 | ||
| Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. | Q54950358 | ||
| BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study | Q56968709 | ||
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation | Q57107580 | ||
| A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer | Q57305942 | ||
| Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer | Q57808778 | ||
| BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients | Q57990746 | ||
| Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response - final results from GeparSixto | Q58592505 | ||
| Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing | Q58797082 | ||
| Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | Q62022868 | ||
| Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | Q62583133 | ||
| OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer | Q64242044 | ||
| Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel | Q64273108 | ||
| Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk | Q64279327 | ||
| AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019 | Q90318502 | ||
| AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019 | Q90318508 | ||
| A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) | Q90622495 | ||
| Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer | Q90961642 | ||
| Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer | Q90961646 | ||
| ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach | Q91771984 | ||
| Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial | Q91841847 | ||
| NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto | Q91974145 | ||
| International evaluation of an AI system for breast cancer screening | Q92365657 | ||
| AI shows promise for breast cancer screening | Q92365709 | ||
| Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes | Q92480972 | ||
| Implementation of machine learning into clinical breast MRI: Potential for objective and accurate decision-making in suspicious breast masses | Q93061792 | ||
| Genome-wide association studies identify four ER negative-specific breast cancer risk loci | Q24622610 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair | Q28267893 | ||
| Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
| Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer | Q29417100 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment | Q34074094 | ||
| Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial | Q34384718 | ||
| A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population | Q35089479 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer | Q35755874 | ||
| 19p13.1 is a triple-negative-specific breast cancer susceptibility locus | Q35871567 | ||
| A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density | Q35957063 | ||
| Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
| The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk | Q36600605 | ||
| Genome-wide association analysis identifies three new breast cancer susceptibility loci | Q36842233 | ||
| Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer | Q36859142 | ||
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | Q36897003 | ||
| GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer | Q36956156 | ||
| Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation | Q37342144 | ||
| Pathological complete response in neoadjuvant treatment of breast cancer | Q38366388 | ||
| Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial | Q38373098 | ||
| Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 | ||
| Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk | Q38823212 | ||
| Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement | Q39014715 | ||
| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | Q39348799 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P304 | page(s) | 277-287 | |
| P577 | publication date | 2020-03-04 | |
| P1433 | published in | Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis | Q26841999 |
| P1476 | title | Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies | |
| P478 | volume | 80 |
Search more.